Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner
Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase 1 trial (NCT04234113)
– Poster shows new preclinical data detailing anti-tumor efficacy in tumor mouse models
– SO-C101 monotherapy significant reduced tumor growth in early and advanced treatment settings
– SO-C101 in combination with PD-1 inhibitors led to durable tumor response in a majority of mice, which was maintained after tumor re-challenge